Mn Services Vermogensbeheer B.V. Buys 38,800 Shares of Pfizer Inc. $PFE

Mn Services Vermogensbeheer B.V. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 2,159,000 shares of the biopharmaceutical company’s stock after purchasing an additional 38,800 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Pfizer were worth $55,011,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PFE. Curio Wealth LLC grew its stake in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the period. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer during the third quarter valued at approximately $29,000. Harbor Asset Planning Inc. bought a new position in shares of Pfizer in the second quarter worth approximately $29,000. Howard Hughes Medical Institute purchased a new stake in shares of Pfizer in the second quarter worth $30,000. Finally, True Wealth Design LLC raised its position in shares of Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: NICE recommended Pfizer’s PARP inhibitor Talzenna for adults with prostate cancer — a UK endorsement that supports incremental oncology revenue and validates Pfizer’s targeted‑therapy strategy. NICE backs Pfizer’s Talzenna for adults with prostate cancer
• Positive Sentiment: Pfizer launched a large Phase 3 lung‑cancer trial positioning its regimen against Merck’s Keytruda — a successful outcome would target a high‑value oncology market and materially boost long‑term growth expectations. Pfizer Takes Aim at Keytruda in New Phase 3 Lung Cancer Study: What Investors Should Know
• Positive Sentiment: Pfizer moved a COPD candidate into a Phase 2/3 trial, strengthening its post‑COVID respiratory pipeline and the company’s addressable market in chronic lung disease. Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline
• Positive Sentiment: Novavax and Pfizer reached a licensing agreement on the Matrix‑M adjuvant — this could reshape Pfizer’s vaccine platform strategy by expanding adjuvant options and serviceable vaccine markets. Novavax inks license agreement with Pfizer
• Positive Sentiment: Early‑stage pipeline progress: PF‑07248144 advanced with a drug–interaction study and PF‑08065010 entered Phase 1 — steady, low‑visibility pipeline work that reduces binary risk over time. Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress
• Neutral Sentiment: Large options flow: traders bought ~446,836 call options (≈+114% vs. typical volume) — indicates short‑term bullish/speculative positioning but not a direct fundamental signal. (Market data)
• Neutral Sentiment: CEO Albert Bourla publicly criticized RFK Jr.’s vaccine views and warned the U.S. risks falling behind China in health research — a strong management stance on science and policy that can influence regulatory/public perception but is not an immediate earnings driver. Pfizer CEO Calls RFK’s Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research
• Negative Sentiment: Investor concerns persist on pricing and post‑COVID revenue sustainability — recent pieces question whether Pfizer’s current valuation reflects secular headwinds and pricing pressure, which helps explain selling pressure despite pipeline news. Is Pfizer (PFE) Pricing Make Sense After Post Covid Slowdown Concerns
• Negative Sentiment: Opinion pieces highlight a debate whether Pfizer is an attractive dividend/value play or a value trap — ongoing skepticism around growth prospects can keep the stock depressed. Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

Pfizer Price Performance

NYSE:PFE opened at $25.65 on Friday. The business’s 50-day moving average is $25.40 and its 200 day moving average is $25.01. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company has a market capitalization of $145.82 billion, a P/E ratio of 14.91 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on PFE shares. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. HSBC reiterated a “buy” rating and set a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $27.88.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.